https://www.selleckchem.com/products/sar405.html
mor tissues at a multi-omics level for a comprehensive molecular understanding of anti-EGFR SR in CRC. Our study demonstrates that SR PDX tumors provide a unique platform to study molecular SR mechanisms and allow testing of multiple treatments for efficient targeting of SR mechanisms, not possible in the patient. Importantly, it suggests that the development of anti-EGFR tolerant cells via transcriptional reprogramming as a cause of anti-EGFR SR in CRC is likely more prevalent than previously anticipated. It emphasizes the need for anal
Like
Comment
Share
